Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022010353 - METHODS FOR IDENTIFYING CORONAVIRUS CROSS-REACTING ANTIBODIES

Publication Number WO/2022/010353
Publication Date 13.01.2022
International Application No. PCT/NL2021/050435
International Filing Date 09.07.2021
IPC
G01N 33/569 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
A61K 39/215 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
CPC
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
C07K 2317/21
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
21from primates, e.g. man
C07K 2317/33
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
C07K 2317/622
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
60characterized by non-natural combinations of immunoglobulin fragments
62comprising only variable region components
622Single chain antibody (scFv)
G01N 2333/165
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Applicants
  • LEYDEN LABORATORIES B.V. [NL]/[NL]
Inventors
  • GOUDSMIT, Jaap
  • VAN GILS, Marit Johanna
  • SANDERS, Rogier Willem
Agents
  • WITMANS, H.A.
Priority Data
202604310.07.2020NL
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR IDENTIFYING CORONAVIRUS CROSS-REACTING ANTIBODIES
(FR) PROCÉDÉS D'IDENTIFICATION D'ANTICORPS À RÉACTION CROISÉE CONTRE LES CORONAVIRUS
Abstract
(EN) The disclosure provides methods for identifying coronavirus cross-reacting antibodies. Such antibodies bind to at least part of the S2 ectodomain of the S protein of at least one common human coronavirus selected from HCoV-NL63, HCoV-OC43, HCoV-229E and HCoV-HKU1 and bind to at least part of the S2 ectodomain of the S protein of at least one highly pathogenic human coronavirus selected from SARS-CoV- 1, MERS-CoV and SARS-CoV-2. Antibodies identified by the methods described herein are particularly useful for treating or preventing coronaviral infections, in particular against highly pathogenic coronaviruses such as SARS-CoV-1, MERS-CoV and/or SARS-CoV-2 as well as cross-species transmission of typically non-human coronaviruses.
(FR) La divulgation concerne des procédés d'identification des anticorps à réaction croisée contre les coronavirus. Lesdits anticorps se lient à au moins une partie de l'ectodomaine S2 de la protéine S d'au moins un coronavirus humain commun choisi parmi HCoV-NL63, HCoV-OC43, HCoV-229E et HCoV-HKU1 et se lient à au moins une partie de l'ectodomaine S2 de la protéine S d'au moins un coronavirus humain hautement pathogène choisi parmi le SARS-CoV-1, le MERS-CoV et le SARS-CoV-2. Les anticorps identifiés par les procédés décrits dans les présentes sont particulièrement utiles pour le traitement ou la prévention d'infections coronavirales, en particulier contre des coronavirus hautement pathogènes tels que le SARS-CoV-1, le MERS-CoV et/ou le SARS-CoV-2, mais aussi la transmission inter-espèces de coronavirus typiquement non humains.
Latest bibliographic data on file with the International Bureau